Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from GlaxoSmithKline ( (GB:GSK) ).
GSK has continued its existing share buyback programme, repurchasing 410,000 ordinary shares on 18 February 2026 through BNP Paribas at a volume‑weighted average price of 2,268.77 pence, with the shares to be held in treasury. The transactions lift total purchases since 17 February to 830,000 shares and leave GSK with 4,075,421,475 shares in issue, of which 5.91% are held in treasury, information the company says shareholders can use to calculate voting rights and disclosure thresholds under U.K. rules.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £20.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company focused on developing and manufacturing prescription medicines, vaccines and specialty healthcare products. The group operates primarily in major global markets, with a strong presence in the U.K. and Europe, and targets both primary care and specialty disease areas across a wide patient base.
Average Trading Volume: 8,759,435
Technical Sentiment Signal: Buy
Current Market Cap: £90.34B
For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.